Wedbush reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research report report published on Thursday, AnalystRatings.com reports. They currently have a $46.00 price target on the stock.
A number of other equities analysts also recently commented on the company. Cowen reissued a buy rating on shares of G1 Therapeutics in a research report on Sunday, August 9th. BidaskClub raised G1 Therapeutics from a strong sell rating to a sell rating in a research report on Friday, August 14th. Zacks Investment Research downgraded G1 Therapeutics from a buy rating to a hold rating in a research report on Friday, June 19th. JPMorgan Chase & Co. lowered their price objective on G1 Therapeutics from $33.00 to $23.00 and set an overweight rating for the company in a research report on Tuesday, May 12th. Finally, HC Wainwright reissued a buy rating and set a $82.00 price objective on shares of G1 Therapeutics in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. G1 Therapeutics presently has an average rating of Buy and an average price target of $54.88.
NASDAQ GTHX traded down $0.52 during trading on Thursday, hitting $15.76. The stock had a trading volume of 8,828 shares, compared to its average volume of 704,413. The company has a market capitalization of $602.53 million, a PE ratio of -4.72 and a beta of 2.04. The company has a quick ratio of 10.95, a current ratio of 10.95 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average price of $18.04 and a 200 day moving average price of $16.76. G1 Therapeutics has a twelve month low of $8.80 and a twelve month high of $41.80.
G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, August 5th. The company reported ($0.83) earnings per share for the quarter, meeting the consensus estimate of ($0.83). On average, sell-side analysts anticipate that G1 Therapeutics will post -2.83 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Advisers LP lifted its stake in G1 Therapeutics by 80.0% in the first quarter. Two Sigma Advisers LP now owns 106,616 shares of the company’s stock valued at $1,175,000 after buying an additional 47,400 shares during the last quarter. Two Sigma Investments LP lifted its stake in G1 Therapeutics by 81.0% in the first quarter. Two Sigma Investments LP now owns 121,049 shares of the company’s stock valued at $1,334,000 after buying an additional 54,178 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in G1 Therapeutics by 309.3% in the first quarter. BNP Paribas Arbitrage SA now owns 17,473 shares of the company’s stock valued at $193,000 after buying an additional 13,204 shares during the last quarter. Morgan Stanley lifted its stake in G1 Therapeutics by 118.2% in the first quarter. Morgan Stanley now owns 152,381 shares of the company’s stock valued at $1,678,000 after buying an additional 82,547 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in G1 Therapeutics in the first quarter valued at approximately $209,000. Institutional investors own 75.77% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Recommended Story: What does it mean to hold a stock in street name?
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.